STAT3 and familial pancreatic carcinoma: Ruxolitinib reportedly inhibited STAT3 activity in pancreatic cancer cells, leading to reversing tumor-mediated immune suppression to enhance T cell activation; however, whether pyroptosis of the pancreatic cancer cells occurred was uncertain [44, 53].